Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is...
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the...
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising...
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study...
Evaxion’s AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all...
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.